<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683501</url>
  </required_header>
  <id_info>
    <org_study_id>DNB-001-CT001</org_study_id>
    <secondary_id>EudoraCT 2006-003907-38</secondary_id>
    <nct_id>NCT00683501</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, and Pharmacokinetic Profile of DNB-001 in Subjects With Elevated Intraocular Pressure</brief_title>
  <acronym>DNB-001</acronym>
  <official_title>A Phase II Study to Investigate the Safety, Efficacy, and Pharmacokinetic Profile of Twice-Daily DNB-001 in Previously Untreated Patients With Elevated Intraocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danube Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danube Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase 1I Study
      to Investigate the Safety, Efficacy, and Pharmacokinetic Profile of Twice-Daily DNB-001 in
      Previously Untreated Patients with intraocular Hypertension
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy of four dosages of mg DNB-001 administered twice daily (bid) per os
      (p.o.) as an anti-ocular hypertensive agent, compared with placebo administered bid po, for
      28 days, in patients with ocular hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The reduction of IOP as calculated on the basis of the arithmetic mean of up to six measurements of IOP, comparing baseline to visit 6</measure>
    <time_frame>28 days of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change and responder rates - e.g., &gt; 20% reduction in lOP values from baseline to Day 21, Day 14 and Day 7</measure>
    <time_frame>7, 14, 21 days of therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Elevated IOP</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage X mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage Y mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage Z mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage 2Z mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNB-001</intervention_name>
    <description>four dosages of DNB-001, one placebo dosage</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, at least 18 years old, in general good health, not presently treated
             for elevated intraocular pressure (IOP), with best corrected Early Treatment Diabetic
             Retinopathy Study (ETDRS) visual acuity score equivalent to a Snellen score of 20/50
             or better in each eye and lOP of 21 to 29 mm Hg at baseline.

        Exclusion Criteria:

          -  Use of intraocular pressure lowering medication within the past 3 months or any
             history of ocular surgery for glaucoma

          -  Evidence of potential angle closure by gonioscopy

          -  Abnormal optic disc or visual field consistent with glaucoma

          -  Use of topical ocular medications during the study and any evidence of systemic
             disease that might interfere with the conduct of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barrett Katz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CEO, CMO, Danube Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Omnicare Clinical Research Center</name>
      <address>
        <city>Chippenham</city>
        <state>Wiltshire</state>
        <zip>SN14 6NQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2008</study_first_posted>
  <last_update_submitted>June 2, 2009</last_update_submitted>
  <last_update_submitted_qc>June 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mr. Clive Migdal</name_title>
    <organization>Western Eye Hospital</organization>
  </responsible_party>
  <keyword>ocular hypertension</keyword>
  <keyword>elevated IOP</keyword>
  <keyword>glaucoma</keyword>
  <keyword>neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

